Benzinga | Nov 1, 2021 08:12AM EDT

Immatics To Present Update On Lead ACTengine Program IMA203 Targeting PRAME At The Society For Immunotherapy Of Cancer's 36th Annual Meeting

Immatics N.V. (NASDAQ:IMTX, &ldquo, Immatics&rdquo, ))), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company will provide an update on its ACTengine(r) IMA203 trial in a late-breaking oral presentation as well as an update on Immatics' next-generation CD8ab TCR-T approach at the 36th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC). The conference will take place, both in person and virtually, from November 10 - 14, 2021.

Today, SITC announced presentation titles and timings as follows:

IMA203 Phase 1a Clinical Data Update:

Presentation Title: Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses -- clinical update on the ACTengine(r) IMA203 trial

Speaker: Martin Wermke, MD, Coordinating Investigator of Immatics ACTengine(r) trials in Germany and Head of the Early Clinical Trial Unit of the National Center for Tumor Diseases Dresden (NCT/UCC) at the University Hospital Carl Gustav Carus in Dresden, Germany

Abstract Number: 959

Category Late-breaking oral abstract presentation

Date & Time: Saturday, November 13, 2021; 12:00 - 12:15 pm EDT

Next-generation CD8ab TCR-T approach - Preclinical Data Update:

Presentation Title: Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression

Speaker: Mamta Kalra, PhD, Director CMC (Process Development) at Immatics

Abstract Number: 163

Category: Poster abstract presentation

Date & Time: Friday, November 12, 2021; Poster Hall Hours: 7 am--8:30 pm EDT



All posters presented at the poster hall will be made available as virtual ePosters throughout the SITC 36th Annual Meeting.